ИСТИНА |
Войти в систему Регистрация |
|
ИПМех РАН |
||
There is an urgent need for the discovery of new drugs with novel modes of biological action, because several diseases develop resistances to known drugs. Metal compounds (metal-based drugs) might offer biological and chemical diversity that is distinct from that of organic substances. Nowadays metal-based drugs are a commercially important sector of the pharmaceutical market. It has become increasingly apparent that metal-based pharmaceuticals can play a crucial role in oncology, treatment of metabolism- and genetic disorders, cardiovascular disease, gene therapy, inflammation, stroke, diabetes, malaria, and neurological disease. The goal of medicinal chemists is to create new inorganic molecules as drug candidates. We will discuss the need for rationalization of the investigational approaches available to create hybrid metal-based drugs. Our key approaches were (1) to maintain the interaction with the target, and (2) to keep the balance between the antitumor potency and general toxicity.
№ | Имя | Описание | Имя файла | Размер | Добавлен |
---|---|---|---|---|---|
1. | Полный текст | Milaeva_EICC5.pdf | 1,4 МБ | 3 сентября 2019 [alexnaz] |